Search

Search Constraints

You searched for: Author/Creator Johansson, Peter A.

Search Results

1. A rare missense variant in protection of telomeres 1 (POT1) predisposes to a range of haematological malignancies. (20th November 2020)

2. Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. Issue 8 (25th August 2020)

3. DECLARE‐TIMI 58: Participants' baseline characteristics. Issue 5 (14th February 2018)

4. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Issue 22 (28th May 2019)

5. Germline variants in oculocutaneous albinism genes and predisposition to familial cutaneous melanoma. (6th July 2019)

9. Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE‐TIMI 58 study. Issue 8 (27th April 2020)